Viral-Specific T-cell Therapy for Post-Transplant Viral Infections

This trial tests a new treatment called VST (Virus-Specific T-cells), which uses special T-cells to combat viral infections like CMV and ADV in patients who have undergone a stem cell transplant. The goal is to determine if these T-cells can reduce the virus in the blood and aid in safer, more effective recovery. The trial seeks patients who have had a transplant and still experience these infections despite treatment. Participants should not have severe infections or conditions requiring intensive medical support. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant medical advancements.

The trial information does not specify if you need to stop taking your current medications. However, if you are on steroids greater than 0.5 mg/kg prednisone equivalent, you may not be eligible to participate.

Research has shown that special immune cells, called virus-specific T cells (VSTs), have been safely used in other studies to treat viral infections after stem cell transplants. For instance, patients who received these cells for CMV, a common virus that can be dangerous post-transplant, experienced good results with few safety issues. Patients have tolerated these cells well, whether from donors or other sources.

Researchers are excited about Viral-Specific T-cell Therapy (VST) because it offers a personalized approach to fighting post-transplant viral infections. Unlike traditional antiviral medications, which broadly target viruses, VST harnesses the power of the immune system by using T-cells specifically trained to recognize and attack virus-infected cells. This targeted action not only promises more effective viral control but also reduces the risk of harming healthy cells, potentially leading to fewer side effects. Additionally, VST could provide a solution for patients who do not respond well to standard antiviral treatments or who experience frequent relapses.

Research has shown that special immune cells called virus-specific T-cells (VSTs) can help treat viral infections like CMV and ADV after a transplant. In this trial, participants will be divided into two cohorts to receive VSTs. One study found that 80% of patients with active viral infections improved after receiving VSTs. These T-cells directly attack the viruses, reducing the virus levels in the body. Another study also found that VSTs are effective against several viruses, including CMV and ADV. Overall, VSTs have strong potential to reduce infections in transplant patients.¹⁵⁶⁷⁸